Health Notices




NEW ZEALAND GAZETTE, No. 49

3 MAY 2012


Health

Burial and Cremation Act 1964

Appointment of Trustees—Te Aute Private Burial Ground

Pursuant to section 34 of the Burial and Cremation Act 1964, and acting under delegation from the Minister of Health, I, Darren Hunt, Acting Director of Public Health, Ministry of Health, appoint (in place of Royston Hereaiterangi Seymour who is deceased):

Stephen Daniel Cave
Grant Campbell Dixon
Miles Edward McBain
Kingi Renata

to be trustees of the Te Aute Private Burial Ground together with

Hugh McBain
Adrian Patrick Kinross White

James Philip Hector Graham†
Leslie Heni Sharon Ellison-Hunter†

(previously appointed) to have the care and maintenance of the Te Aute private burial ground, being the land described in the Schedule to this notice.

Hawke’s Bay Land District—Maraekakaho Survey District Schedule

Area Description
5382 Being Lot 27 DP 4386 (Identifier HB147/90).

Dated at Wellington this 24th day of April 2012.

DR DARREN HUNT, Acting Director of Public Health.

*New Zealand Gazette, 17 March 1977, No. 31, page 623
†New Zealand Gazette, 25 September 2008, No. 143, page 3894

go2554

Medicines Act 1981

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:

Schedule

Product:
Dopergin

Active Ingredient:
Lisuride maleate 0.2mg

Dosage Form:
Tablet

New Zealand Sponsor:
Bayer New Zealand Limited

Manufacturer:
Delpharm Lille SAS, Lys Lez Lannoy, France

Dated this 26th day of April 2012.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
(pursuant to delegation given by the Minister of Health on 6 July 2001).

go2570

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product:
Hyprosol

Active Ingredient:
Hypromellose 0.03g

Dosage Form:
Eye drops, solution

New Zealand Sponsor:
Beximco Pharmaceuticals New Zealand Limited

Manufacturer:
Beximco Pharmaceuticals Limited, Gazipur, Bangladesh

Product:
Meropenem Alphapharm

Active Ingredient:
Meropenem trihydrate 570.4mg equivalent to Meropenem anhydrous 500mg

Dosage Form:
Powder for injection

New Zealand Sponsor:
Mylan New Zealand Limited

Manufacturer:
LDP Laboratorios Torlan S.A, Barcelona, Spain

Product:
Meropenem Alphapharm

Active Ingredient:
Meropenem trihydrate 1140.8mg equivalent to Meropenem anhydrous 1000mg

Dosage Form:
Powder for injection

New Zealand Sponsor:
Mylan New Zealand Limited

Manufacturer:
LDP Laboratorios Torlan S.A, Barcelona, Spain



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2012, No 49





✨ LLM interpretation of page content

🏥 Appointment of Trustees for Te Aute Private Burial Ground

🏥 Health & Social Welfare
24 April 2012
Burial and Cremation Act 1964, Trustees, Te Aute Private Burial Ground, Hawke’s Bay Land District
8 names identified
  • Stephen Daniel Cave, Appointed trustee
  • Grant Campbell Dixon, Appointed trustee
  • Miles Edward McBain, Appointed trustee
  • Kingi Renata, Appointed trustee
  • Hugh McBain, Previously appointed trustee
  • Adrian Patrick Kinross White, Previously appointed trustee
  • James Philip Hector Graham, Previously appointed trustee
  • Leslie Heni Sharon Ellison-Hunter, Previously appointed trustee

  • Darren Hunt, Acting Director of Public Health

🏥 Consent to Distribution of Dopergin

🏥 Health & Social Welfare
26 April 2012
Medicines Act 1981, New medicine, Dopergin, Lisuride maleate
  • Don Mackie, Chief Medical Officer

🏥 Consent to Distribution of Hyprosol, Meropenem Alphapharm

🏥 Health & Social Welfare
26 April 2012
Medicines Act 1981, New medicines, Hyprosol, Meropenem Alphapharm, Hypromellose, Meropenem trihydrate
  • Don Mackie, Chief Medical Officer